» Articles » PMID: 38996035

Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia

Abstract

Background: Cholera is a public health priority in Ethiopia. The Ethiopian National Cholera Plan elaborates a multi-year scheme of oral cholera vaccine (OCV) use. Aligned with this, a preemptive OCV campaign was conducted under our Ethiopia Cholera Control and Prevention project. Here, we present the OCV vaccination outcomes.

Method: Cholera high-priority hotspots in the Oromia Region, Shashemene Town (ST) and Shashemene Woreda (SW), were selected. Four kebelles (Abosto, Alelu, Arada, and Awasho) in ST and 4 clusters (Faji Gole, Harabate, Toga, and Chabi) in SW were study sites with OCV areas nested within. A total of 40 000 and 60 000 people in ST and SW, respectively, were targeted for a 2-dose OCV (Euvichol-Plus) campaign in 11-15 May (first round [R1]) and 27-31 May (second round [R2]) 2022. Daily administrative OCV coverage and a coverage survey in 277 randomly selected households were conducted.

Results: The administrative OCV coverage was high: 102.0% for R1 and 100.5% for R2 in ST and 99.1% (R1) and 100.0% (R1) in SW. The coverage survey showed 78.0% (95% confidence interval [CI]: 73.1-82.9) of household members with 2-dose OCV and 16.8% (95% CI: 12.4-21.3) with no OCV in ST; and 83.1% (95% CI: 79.6-86.5) with 2-dose OCV and 11.8% (95% CI: 8.8-14.8) with no OCV in SW. The 2-dose coverages in 1-4-, 5-14-, and ≥15-year age groups were 88.3% (95% CI: 70.6-96.1), 88.9% (95% CI: 82.1-95.7), and 71.3% (95% CI: 64.2-78.3), respectively, in ST and 78.2% (95% CI: 68.8-87.7), 91.0% (95% CI: 86.6-95.3), and 78.7% (95% CI: 73.2-84.1) in SW.

Conclusions: High 2-dose OCV coverage was achieved. Cholera surveillance is needed to assess the vaccine impact and effectiveness.

Citing Articles

Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.

Edosa M, Jeon Y, Gedefaw A, Hailu D, Getachew E, Mogeni O Clin Infect Dis. 2024; 79(Supplement_1):S20-S32.

PMID: 38996040 PMC: 11244176. DOI: 10.1093/cid/ciae194.


Ethiopia National Cholera Elimination Plan 2022-2028: Experiences, Challenges, and the Way Forward.

Hussen M, Demlie Y, Edosa M, Kebede M, Wossen M, Mulugeta Chane A Clin Infect Dis. 2024; 79(Supplement_1):S1-S7.

PMID: 38996038 PMC: 11244260. DOI: 10.1093/cid/ciae200.

References
1.
Teshome S, Desai S, Kim J, Belay D, Mogasale V . Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia. Hum Vaccin Immunother. 2018; 14(10):2427-2433. PMC: 6290934. DOI: 10.1080/21645515.2018.1460295. View

2.
Kar S, Sah B, Patnaik B, Kim Y, Kerketta A, Shin S . Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model. PLoS Negl Trop Dis. 2014; 8(2):e2629. PMC: 3916257. DOI: 10.1371/journal.pntd.0002629. View

3.
Desai S, Akalu Z, Teferi M, Manna B, Teshome S, Park J . Comparison of immune responses to a killed bivalent whole cell oral cholera vaccine between endemic and less endemic settings. Trop Med Int Health. 2015; 21(2):194-201. DOI: 10.1111/tmi.12641. View

4.
Luquero F, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M . Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med. 2014; 370(22):2111-20. DOI: 10.1056/NEJMoa1312680. View

5.
Baik Y, Keun Choi S, Olveda R, Espos R, Ligsay A, Montellano M . A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015; 33(46):6360-5. DOI: 10.1016/j.vaccine.2015.08.075. View